Alnylam Pharmaceuticals (ALNY) News Today $280.96 -9.74 (-3.35%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$287.30 +6.34 (+2.25%) As of 03/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by JPMorgan Chase & Co.JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price target for the company from $280.00 to $328.00 in a research report on Monday.March 25 at 8:12 AM | marketbeat.comKLP Kapitalforvaltning AS Invests $10.28 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)KLP Kapitalforvaltning AS purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 43,700 shares of the biopharmaceutical company's stock, valued at approximatelMarch 25 at 4:48 AM | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Rating Increased to Overweight at JPMorgan Chase & Co.March 25 at 1:55 AM | americanbankingnews.comAlnylam upgraded to Overweight from Neutral at JPMorganMarch 25 at 12:28 AM | markets.businessinsider.comAlnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades StockMarch 24 at 3:06 PM | benzinga.comCrowley Wealth Management Inc. Buys New Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Crowley Wealth Management Inc. purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,250 shares of the biopharmaceutical compaMarch 24 at 7:18 AM | marketbeat.comAXQ Capital LP Purchases Shares of 1,644 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)AXQ Capital LP purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,644 shares of the biopharmaceutical company's stock, valued aMarch 24 at 5:11 AM | marketbeat.comAlnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA DecisionMarch 24 at 4:22 AM | finance.yahoo.comScotiabank Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) StockMarch 24 at 3:47 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $325.00March 24 at 3:47 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $351.00March 24 at 2:25 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $390.00March 24 at 1:49 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Receives Outperform Rating from William BlairMarch 24 at 1:49 AM | americanbankingnews.comAlnylam Pharmaceuticals' (ALNY) Buy Rating Reaffirmed at Chardan CapitalMarch 24 at 1:49 AM | americanbankingnews.comAmerican Century Companies Inc. Purchases 11,291 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)American Century Companies Inc. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,604,024 shares of the biopharmaceutical company's stock aftMarch 23 at 6:33 AM | marketbeat.comTeacher Retirement System of Texas Purchases 5,425 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Teacher Retirement System of Texas lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 16.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,075 sharesMarch 23 at 4:34 AM | marketbeat.comCibc World Markets Corp Has $1.37 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Cibc World Markets Corp reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 21.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,810 shares of the biopharmaceutical company's stock after selling 1,561 shares duringMarch 23 at 4:09 AM | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given "Buy" Rating at Needham & Company LLCMarch 23 at 2:05 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by StockNews.comMarch 23 at 2:05 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $330.00 at Royal Bank of CanadaMarch 23 at 2:05 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Up After Analyst UpgradeMarch 23 at 1:07 AM | americanbankingnews.comAlnylam trading halted, news pendingMarch 22, 2025 | markets.businessinsider.comCitigroup Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock PriceCitigroup boosted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday.March 22, 2025 | marketbeat.comCanaccord Genuity Group Boosts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $390.00Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday.March 22, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Royal Bank of Canada Analyst SaysRoyal Bank of Canada lifted their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a report on Friday.March 22, 2025 | marketbeat.comAlnylam Pharmaceuticals' (ALNY) "Outperform" Rating Reiterated at William BlairWilliam Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday.March 22, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Up Following Analyst UpgradeAlnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Up After Analyst UpgradeMarch 22, 2025 | marketbeat.comScotiabank Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock PriceScotiabank increased their price objective on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a "sector outperform" rating in a report on Friday.March 22, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $287.00Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday.March 22, 2025 | marketbeat.comAlnylam Heart Drug Approval Sets Up Challenge With PfizerMarch 22, 2025 | msn.comNeedham & Company LLC Reaffirms Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday.March 22, 2025 | marketbeat.comAlnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday.March 22, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Bank of America Analyst SaysBank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday.March 22, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-five brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommMarch 22, 2025 | marketbeat.comAlnylam prices heart drug at premium to rivalsMarch 22, 2025 | finance.yahoo.comAlnylam Pharma (ALNY) Initiated with a Hold at Cantor FitzgeraldMarch 22, 2025 | markets.businessinsider.comAlnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drugMarch 22, 2025 | msn.comAlnylam Stock Jumps After the FDA Approves Its Heart DrugMarch 22, 2025 | wsj.comAlnylam Pharmaceuticals Ready To Go With Its Next BlockbusterMarch 21, 2025 | seekingalpha.comUS FDA expands approval for Alnylam's drug to treat rare heart diseaseMarch 21, 2025 | msn.comAlnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock JumpsMarch 21, 2025 | benzinga.comAlnylam shares rise on expanded heart drug approvalMarch 21, 2025 | reuters.comRoyal London Asset Management Ltd. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Royal London Asset Management Ltd. increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 0.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 281,509 shares of the biopharmaceutical company's stock aMarch 21, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Xponance Inc.Xponance Inc. grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,456 shares of the biopharmaceutical company's stock after acquiringMarch 21, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by StockNews.com to HoldStockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday.March 21, 2025 | marketbeat.comAlnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)March 20, 2025 | businesswire.comUS FDA approves Alnylam's drug for rare heart conditionMarch 20, 2025 | reuters.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 22.7% in FebruaryMarch 17, 2025 | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest UpdateAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 2,490,000 shares, a decrease of 22.7% from the February 13th total of 3,220,000 shares. Approximately 2.0% of the shares of the company are sold short. Based on an average daily trading volume, of 676,300 shares, the days-to-cover ratio is currently 3.7 days.March 17, 2025 | marketbeat.comSwiss National Bank Trims Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Swiss National Bank trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 362,600 shares of the biopharmaceutical company's stock after sellingMarch 16, 2025 | marketbeat.com Remove Ads Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.710.74▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼5913▲ALNY Articles Average Week Remove Ads Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Gilead Sciences News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Biogen News United Therapeutics News BioMarin Pharmaceutical News Incyte News Neurocrine Biosciences News Exelixis News Exact Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALNY Stock Free ALNY Stock Alerts